CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation SummitFormat:        Fireside chatDate/Time:        Wednesday, May 29, 2024, at 9:00 a.m. Ea ...